Xcout Intel
Vilya
Launched in 2022 and headquartered in Seattle, Washington, Vilya is an AI peptide company co-founded by scientists from the Institute of Protein Design. The company uses artificial intelligence and synthetic biology to design novel macrocycle therapeutics inspired by nature.
Subscribe to see Vilya’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vilya at a glance
Vilya is a biotech company headquartered in United States. Xcout tracks 12 named people at Vilya, including Cyrus Harmon (Chief Executive Officer).
Vilya leadership
- Cyrus HarmonChief Executive Officer
- Nancy PryerCSO
- Lance StewartCo-Founder, CSO & COO, IPD
- Patrick SalvesonCo-Founder, CTO
- Adam MoyerCo-Founder, VP of Molecular Design
- Nao HiranumaCo-Founder, Director of Machine Learning
6 more named people on record for Vilya, with roles, board committees and tenure — see the full roster →
Vilya competitors
A few of Vilya's closest competitors — see the full list of competitors and alternatives →
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Enveda Biosciences (Enveda Therapeutics Inc.) is a biotechnology research company headquartered in Boulder, Colorado. The company leverages artificial intelligence to discover novel therapeutics and chemical compounds derived from natural sources.
Atomic AI is a biotechnology research company specializing in RNA drug discovery utilizing atomic precision. Headquartered in San Francisco, California, the company combines machine learning and biology to develop advanced therapeutics.
Metaphore Biotechnologies, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, operating as part of Flagship Pioneering. The company focuses on therapeutic design, leveraging AI and machine learning technologies for drug discovery and development.
Get Vilya's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Vilya in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access